Associated Papers
Effect of donor GSTM3 rs7483 genetic variant on tacrolimus elimination in the early period after liver transplantation.
Zhang T et al.
Peerj, 2024
Points-to-consider documents: Scientific information on the evaluation of genetic polymorphisms during non-clinical studies and phase I clinical trials in the Japanese population.
Hiratsuka M et al.
Drug Metabolism and Pharmacokinetics, 2018
Distribution of polymorphic variants of CYP2A6 and their involvement in nicotine addiction.
López-Flores LA et al.
Excli Journal, 2017
CYP2A7 pseudogene transcript affects CYP2A6 expression in human liver by acting as a decoy for miR-126.
Nakano M et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals, 2015
CYP2A6 Polymorphisms May Strengthen Individualized Treatment for Nicotine Dependence.
Akrodou YM
Scientifica, 2015
High CYP2A6 enzyme activity as measured by a caffeine test and unique distribution of CYP2A6 variant alleles in Ethiopian population.
Aklillu E et al.
Omics : a Journal of Integrative Biology, 2014
The contribution of common CYP2A6 alleles to variation in nicotine metabolism among European-Americans.
Bloom J et al.
Pharmacogenetics and Genomics, 2011
Associations of various gene polymorphisms with toxicity in colorectal cancer patients receiving oral uracil and tegafur plus leucovorin: a prospective study.
Tsunoda A et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology, 2011
Comparison of the pharmacokinetics and pharmacodynamics of S-1 between Caucasian and East Asian patients.
Chuah B et al.
Cancer Science, 2011
A novel CYP2A6 allele (CYP2A6*35) resulting in an amino-acid substitution (Asn438Tyr) is associated with lower CYP2A6 activity in vivo.
Al Koudsi N et al.
The Pharmacogenomics Journal, 2009
Genotyping panel for assessing response to cancer chemotherapy.
Dai Z et al.
Bmc Medical Genomics, 2008
Novel and established CYP2A6 alleles impair in vivo nicotine metabolism in a population of Black African descent.
Mwenifumbo JC et al.
Human Mutation, 2008
Differences in pharmacogenetics of nicotine and alcohol metabolism: review and recommendations for future research.
Wall TL et al.
Nicotine & Tobacco Research : Official Journal of the Society for Research on Nicotine and Tobacco, 2007
A novel duplication type of CYP2A6 gene in African-American population.
Fukami T et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals, 2007
Comprehensive evaluation of variability in nicotine metabolism and CYP2A6 polymorphic alleles in four ethnic populations.
Nakajima M et al.
Clinical Pharmacology and Therapeutics, 2006
Three haplotypes associated with CYP2A6 phenotypes in Caucasians.
Haberl M et al.
Pharmacogenetics and Genomics, 2005
CYP2A6 genetic polymorphisms and correlation with smoking status in Brazilians.
Vasconcelos GM et al.
The Pharmacogenomics Journal, 2005
Polymorphic NF-Y dependent regulation of human nicotine C-oxidase (CYP2A6).
von Richter O et al.
Pharmacogenetics, 2004
A nicotine C-oxidase gene (CYP2A6) polymorphism important for promoter activity.
Pitarque M et al.
Human Mutation, 2004